Therapeutic strategies based on granulysin analogues have been studied, showing in vitro activity in cell lines and primary chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) cells [171]. Here, GNLY is linked to B-cell chronic lymphocytic leukemia.